Comparison of Clinical Utility between Phadiatop Assay and AdvanSureTM AlloScreen

ABSTRACT

Background@#Multiple Allergo-Sorbent Test (MAST) allows simultaneous detection of specific IgE antibodies using multiple allergens, and it is commonly used for allergy screening. Phadiatop assay (Phadia AB, Sweden), including Phadiatop test and Phadiatop Infant test, is a variant of specific IgE test that covers a mixture of common allergens. We compared the clinical utility of Phadiatop assay with that of the MAST AlloScreen (LG Life Science, Korea). @*Methods@#A total of 218 samples classified by AlloScreen results were collected. Phadiatop test was performed on sera from 61 and 103 aeroallergen-positive and -negative subjects. Phadiatop Infant test was performed on sera from 54 and 103 food and aeroallergen-positive and -negative subjects. When the results of AlloScreen and Phadiatop assay were not identical, we confirmed them using ImmunoCAP (Phadia AB). @*Results@#The concordance rate between AlloScreen and Phadiatop test was 93.2% (κ=0.86, P<0.001). Eleven (6.7%) of 164 specimens showed discrepant results. The results of AlloScreen did not agree with those of ImmunoCAP. The concordance rate between AlloScreen and Phadiatop Infant test was 97.4% (κ=0.945, P <0.001). Four (2.5%) specimens showed negative results in AlloScreen and positive results in Phadiatop Infant test. Three cases were confirmed as positive and one case was not confirmed through ImmunoCAP. @*Conclusions@#There was excellent agreement between AlloScreen and Phadiatop assay. Phadiatop assay accurately detected sensitization to common food and aeroallergen mixes. Therefore, Phadiatop assay is recommended as a screening test for allergic diseases.